Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Amina Arroul-Lammali, Fadia Rahal, Radia Chetouane, Zineb Djeraba, Oussama Medjeber, Aicha Ladjouze-Rezig & Chafia Touil-Boukoffa. (2017) Ex vivo all-trans retinoic acid modulates NO production and regulates IL-6 effect during rheumatoid arthritis: a study in Algerian patients. Immunopharmacology and Immunotoxicology 39:2, pages 87-96.
Read now
Read now
Tomohiro Koga, Kiyoshi Migita & Atsushi Kawakami. (2016) Biologic therapy in familial Mediterranean fever. Modern Rheumatology 26:5, pages 637-641.
Read now
Read now
Eiichi Tanaka, Eisuke Inoue, Daisuke Hoshi, Yoko Shimizu, Akiko Kobayashi, Naoki Sugimoto, Kumi Shidara, Eri Sato, Yohei Seto, Ayako Nakajima, Shigeki Momohara, Atsuo Taniguchi & Hisashi Yamanaka. (2015) Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study. Modern Rheumatology 25:4, pages 503-513.
Read now
Read now
Silvano Sozzani, Maria P. Abbracchio, Vito Annese, Silvio Danese, Ornella De Pità, Giovambattista De Sarro, Sabatino Maione, Ignazio Olivieri, Aurora Parodi & Piercarlo Sarzi-Puttini. (2014) Chronic inflammatory diseases: Do immunological patterns drive the choice of biotechnology drugs? A critical review. Autoimmunity 47:5, pages 287-306.
Read now
Read now
Bernard Bannwarth & Christophe Richez. (2011) Clinical safety of tocilizumab in rheumatoid arthritis. Expert Opinion on Drug Safety 10:1, pages 123-131.
Read now
Read now
Articles from other publishers (16)
Dimitra Koumaki, Stamatios Gregoriou, George Evangelou & Konstantinos Krasagakis. (2023) Pruritogenic Mediators and New Antipruritic Drugs in Atopic Dermatitis. Journal of Clinical Medicine 12:6, pages 2091.
Crossref
Crossref
Yessica Bernal Luna, Alejandro Esquivel Loza & José de Jesús Garduño García. (2022) Emergency Use of Tocilizumab in Moderate and Severe COVID-19 Patients over the Prevaccination Stage during the Pandemic in Mexico. Advances in Virology 2022, pages 1-6.
Crossref
Crossref
Fiona R. Macfarlane, Mark A.J. Chaplain & Raluca Eftimie. (2022) Modelling rheumatoid arthritis: A hybrid modelling framework to describe pannus formation in a small joint. ImmunoInformatics 6, pages 100014.
Crossref
Crossref
Bogna Grygiel-Górniak, Osama Shaikh, Nikita Niranjan Kumar, Shao Heng Hsu & Włodzimierz Samborski. (2021) Use of the rheumatic drug tocilizumab for treatment of SARS-CoV-2 patients. Rheumatology 59:4, pages 252-259.
Crossref
Crossref
Atalay DOĞRU. (2021) Covid-19 Hastalığında Anti-sitokin Tedaviler: IL-6 Reseptör İnhibitörü (Tosilizumab) ve IL-1 Reseptör Antagonisti (Anakinra)Anti-cytokine treatments in Covid-19 disease: IL-6 receptor inhibitor (Tocilizumab) and IL-1 receptor antagonist (Anakinra). SDÜ Tıp Fakültesi Dergisi 28:COVİD-19 ÖZEL SAYI, pages 163-166.
Crossref
Crossref
Nitesh Sanghai, Kashfia Shafiq & Geoffrey K. Tranmer. (2021) Drug Discovery by Drug Repurposing: Combating COVID-19 in the 21st Century. Mini-Reviews in Medicinal Chemistry 21:1, pages 3-9.
Crossref
Crossref
Lara Ionescu Silverman, Will Heaton, Niloofar Farhang, Lindsey Hart Saxon, Galina Dulatova, Daniel Rodriguez-Granrose, Flagg Flanagan & Kevin T. Foley. (2020) Perspectives on the Treatment of Lumbar Disc Degeneration: The Value Proposition for a Cell-Based Therapy, Immunomodulatory Properties of Discogenic Cells and the Associated Clinical Evaluation Strategy. Frontiers in Surgery 7.
Crossref
Crossref
Qiao Zhang, Taizhen Liang, Shuyin Gu, Yilu Ye & Shuwen Liu. (2020) SNW1 interacts with IKKγ to positively regulate antiviral innate immune responses against influenza A virus infection. Microbes and Infection 22:10, pages 576-584.
Crossref
Crossref
Edoardo Conticini, Jurgen Sota, Paolo Falsetti, Caterina Baldi, Marco Bardelli, Francesca Bellisai, Gian Marco Tosi, Bruno Frediani & Luca Cantarini. (2020) The Role of Multimodality Imaging in Monitoring Disease Activity and Therapeutic Response to Tocilizumab in Giant Cell Arteritis. Mediators of Inflammation 2020, pages 1-9.
Crossref
Crossref
Victoria Hall, Douglas Johnson & Joseph Torresi. (2018) Travel and biologic therapy: travel-related infection risk, vaccine response and recommendations. Journal of Travel Medicine 25:1.
Crossref
Crossref
Ping Li, Ying Zheng & Xin Chen. (2017) Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics. Frontiers in Pharmacology 8.
Crossref
Crossref
Tetsu KOBAYASHI, Kazushige MURAYAMA, Yuki OHTA, Nana KAWASAKI, Satoshi TOYOSHIMA & Akiko ISHII-WATABE. (2017) <b>The Safety Profiles of Biological Drugs for Rheumatoid Arthritis </b>. Japanese Journal of Pharmacoepidemiology/Yakuzai ekigaku 21:2, pages 63-76.
Crossref
Crossref
Kostas Athanasakis, Filippos Tarantilis, Konstantina Tsalapati, Thomais Konstantopoulou, Eleni Vritzali & John Kyriopoulos. (2015) Cost-utility analysis of tocilizumab monotherapy in first line versus standard of care for the treatment of rheumatoid arthritis in Greece. Rheumatology International 35:9, pages 1489-1495.
Crossref
Crossref
Gholamreza Azizi, Roobina Boghozian & Abbas Mirshafiey. (2014) The potential role of angiogenic factors in rheumatoid arthritis. International Journal of Rheumatic Diseases 17:4, pages 369-383.
Crossref
Crossref
M. De La Torre, L. Arboleya, S. Pozo, J. Pinto & J. Velasco. (2011) Rapid and sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in a patient with nephrotic syndrome secondary to systemic juvenile idiopathic arthritis-related amyloidosis. Clinical Kidney Journal 4:3, pages 178-180.
Crossref
Crossref
Shigeru Hasegawa, Aiko Sato, Kenji Iesato & Yukihiro Matsuda. (2011) A Case of Rheumatoid Arthritis with Renal Amyloidosis and Nephrotic Syndrome Effectively Treated with Tocilizumab.Tocilizumabによりネフローゼ症候群が寛解した関節リウマチ関連AAアミロイドーシスの1例. Nihon Naika Gakkai Zasshi 100:1, pages 185-187.
Crossref
Crossref